EFFECT OF MODERATE HYPERTRIGLYCERIDEMIA ON THE RELATION OF PLASMA TOTAL AND LDL APO-B LEVELS

被引:70
作者
SNIDERMAN, A [1 ]
VU, H [1 ]
CIANFLONE, K [1 ]
机构
[1] MCGILL UNIV, MCGILL UNIT PREVENT CARDIOVASC DIS, MONTREAL H3A 2T5, QUEBEC, CANADA
基金
英国医学研究理事会;
关键词
HYPERTRIGLYCERIDEMIA; APO-B; HYPERAPOBETALIPOPROTEINEMIA;
D O I
10.1016/0021-9150(91)90050-D
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The risk of premature coronary artery disease is related to an important degree to the number of particles of low density lipoproteins (LDL) in plasma, an estimate given by measurement of LDL apo B. In clinical practise, though, it is total, not LDL apo B, which is measured. The purpose of the present study therefore was to compare plasma total and LDL apo B in the presence and absence of moderate hypertriglyceridemia. The results demonstrate that within the range of plasma triglyceride levels examined, i.e., values of triglyceride up to 500 mg/dl, there is close correspondence between total and LDL apo B, with the latter more than 90% of the former. VLDL composition was also examined and two patterns found in hypertriglyceridemic patients: those with normal apo B had markedly lipid enriched VLDL while those with elevated apo B had VLDL which was normal in composition except for a moderate increase in triglyceride content. Thus total apo B within the circumstances studied reflects principally LDL apo B. Moreover measurement of apo B allows distinction between two different forms of hypertriglyceridemia, only one of which - that with an increased LDL particle number - has previous work shown to be associated with increased coronary risk. Total apo B, therefore, provides additional information not available from conventional plasma and lipoprotein lipids which allows more precise physiologic classification and may lead to more rational choice of pharmacologic therapy in normolipidemic and hypertriglyceridemic patients.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 39 条
[1]  
ALBERS JJ, 1989, J LIPID RES, V30, P1445
[2]   APOPROTEIN MEASUREMENTS AND THEIR CLINICAL-APPLICATION [J].
ALBERS, JJ ;
BRUNZELL, JD ;
KNOPP, RH .
CLINICS IN LABORATORY MEDICINE, 1989, 9 (01) :137-152
[3]   LIPOPROTEINS AND APOLIPOPROTEINS IN YOUNG MALE SURVIVORS OF MYOCARDIAL-INFARCTION [J].
ALMUHTASEB, N ;
HAYAT, N ;
ALKHAFAJI, M .
ATHEROSCLEROSIS, 1989, 77 (2-3) :131-138
[4]  
AUSTIN MA, 1986, LANCET, V2, P592
[5]  
AVOGARO P, 1979, LANCET, V1, P901
[6]   TRADE-OFFS ON CUTPOINTS FOR THE TREATMENT OF HYPERLIPIDEMIA [J].
BLANK, D ;
SILBERBERG, J ;
SNIDERMAN, A .
CORONARY ARTERY DISEASE, 1990, 1 (04) :455-459
[7]   REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298
[8]  
BRUNZELL JD, 1983, J LIPID RES, V24, P147
[9]   MYOCARDIAL-INFARCTION IN FAMILIAL FORMS OF HYPERTRIGLYCERIDEMIA [J].
BRUNZELL, JD ;
SCHROTT, HG ;
MOTULSKY, AG ;
BIERMAN, EL .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1976, 25 (03) :313-320
[10]   APOPROTEIN-B AND APOPROTEIN-A-1 AND CORONARY-ARTERY DISEASE IN HUMANS [J].
BRUNZELL, JD ;
SNIDERMAN, AD ;
ALBERS, JJ ;
KWITEROVICH, PO .
ARTERIOSCLEROSIS, 1984, 4 (02) :79-83